Ocrelizumab (Ocrevus, Roche) has a marketing authorisation in the UK 'for the treatment of adult patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity'.
Ocrelizumab is administered by intravenous infusion. The first dose is administered as 2×300 mg infusions 2 weeks apart; subsequent doses are administered as a single 600 mg infusion every 6 months. There should be a minimum interval of 5 months between each dose.
The list price for ocrelizumab is £4,790 per 300‑mg vial (company submission).
The company has a commercial arrangement. This makes ocrelizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.